What we say:
Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Combinatorial therapy for Deafness: A therapeutic mix encompassing Rolipram, Cholecalciferol, Ajoene and DIM (RPCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via up regulation of its target genes
[easy_payment currency=”USD”]
From Significance of the study to Public health relevance:
Given that: (1) more than one seventh of the global population suffers from hearing impairment; (2) majority of hearing impairment occurs in low and middle income countries, for instance, 3 in 1000 from developed countries, while 6 in 1000 from developing countries suffer from hearing impairment; (3) damage to the auditory hair cells (HCs) is the principal reason for hearing loss; (4) only in 50% cases hearing impairment can be cured; and (5) the global annual economic cost spent for unaddressed hearing loss is estimated to be in the range of $750–790 billions, there is an urgent need to find: (i) a way to promote regeneration, growth and proliferation of auditory hair cells in mammalian cochlea; (ii) a cheaper alternative to the existing expensive drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, hearing impairment.
From research findings to Therapeutic opportunity:
This study provides, for the first time, mechanistic insights into how a pharmaceutical mixture encompassing Rolipram, Cholecalciferol, Ajoene and DIM (RPCAD) may aid in the treatment of hearing impairment.
RPCAD, by increasing the expression of its target genes, it may increase the expression of ATG5 (Autophagy-related protein 5). Thereby, it may: (1) prevent degeneration of adult hair cells; (2) prevent aggregation of polyubiquitinated proteins and p62/SQSTM1 in inclusion bodies; (3) promote maintenance of hair cells morphology and hearing acuity; and (4) prevent hearing loss. Thus, pharmacological mixture encompassing “Rolipram, Cholecalciferol, Ajoene and DIM (RPCAD) or their analogues, either alone or in combination with other drugs, may be used to treat deafness (Fig.1).
Figure 1 Mechanistic insights into how a therapeutic mix encompassing Rolipram, Cholecalciferol, Ajoene and DIM (RPCAD) aids in improving hearing impairment. SFCAD prevents aggregation of proteins, promotes regeneration of adult hair cells and inhibits hearing impairment via up-regulation of its target gene ATG5
Figure 2. The chemical structure of Rolipram
[easy_payment currency=”USD”]
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How does a therapeutic mix encompassing Rolipram, Cholecalciferol, Ajoene and DIM (RPCAD) ncrease the expression of ATG5?
Amount: $500#
For payment and purchase details, you may reach us at admin@genomediscovery.org
# Research cooperation
References:
Web: http://genomediscovery.org or http://newbioideas.com/
Citation: Boominathan, L., Combinatorial therapy for Deafness: A therapeutic mix encompassing Rolipram, Cholecalciferol, Ajoene and DIM (RPCAD) increases the expression of ATG5 (Autophagy-related 5), prevents aggregation of proteins in inclusion bodies, inhibits hair cell degeneration, improves hearing loss via up regulation of its target genes, 15/February/2018, 11.14 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at admin@genomediscovery.org